Biogen Inc. (LON: 0R1B)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 16.89B |
| Revenue (ttm) | 7.17B |
| Net Income (ttm) | 1.21B |
| Shares Out | n/a |
| EPS (ttm) | 8.25 |
| PE Ratio | 14.02 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,799 |
| Average Volume | 3,418 |
| Open | 140.80 |
| Previous Close | 141.85 |
| Day's Range | 139.83 - 143.01 |
| 52-Week Range | 139.83 - 143.01 |
| Beta | -0.06 |
| RSI | 30.40 |
| Earnings Date | Feb 13, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab bio... [Read more]
Financial Performance
In 2023, Biogen's revenue was $9.84 billion, a decrease of -3.32% compared to the previous year's $10.17 billion. Earnings were $1.16 billion, a decrease of -61.89%.
Financial numbers in USD Financial StatementsNews
Sage sues Biogen in wake of $469M buyout offer: report
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders
Analysis of Sage Therapeutics' financials and pipeline setbacks, including an unsolicited offer from Biogen, suggest a hold for investors. Click here to read.
Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Biogen CEO sees no burning need for more acquisitions
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.
Sarepta, Biogen drugs with accelerated approval under fire in FDA report
Biogen stock at lowest level since February 2013 following J.P. Morgan presentation
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review
Biogen Inc (BIIB) Announces FDA Acceptance of LEQEMBI Subcutaneous Autoinjector Application
Biogen Inc (BIIB) Announces FDA Acceptance of LEQEMBI Subcutaneous Autoinjector Application
FDA Accepts Biogen's Application for Subcutaneous Alzheimer's Treatment
FDA Accepts Biogen's Application for Subcutaneous Alzheimer's Treatment
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option LEQEMBI is the only FDA-approved anti-...
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Monday. The Dow traded up 0.13% to 41,992.95 while the NASDAQ dipped 1.42% to 18,888.78. The S&P 5...
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid
Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
Why Sage Therapeutics Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket
Shares of Sage Therapeutics, Inc . (NASDAQ: SAGE) rose sharply in today's pre-market trading after the company confirmed the receipt of Biogen’s nonbinding $7.22/share acquisition proposal . Sage The...
Sage confirms Biogen’s bid to acquire remaining stake
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbi...
Biogen proposes to buy remaining stake in Sage in $442 million deal
Drugmaker Biogen will buy all outstanding shares of Sage Therapeutics that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade.
Peering Into Biogen's Recent Short Interest
Biogen's (NYSE: BIIB) short percent of float has fallen 5.21% since its last report. The company recently reported that it has 2.58 million shares sold short , which is 2.0% of all regular shares tha...
Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer
BURLINGTON, Mass.--(BUSINESS WIRE)--Cardurion Pharmaceuticals, Inc. (“Cardurion”), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of car...
Biogen cut to neutral at Piper Sandler on Alzheimer’s headwinds
Beaten Down Biogen Stock Looks Attractive At Current Levels
Investing pros think these stock-market losers are set to rebound in 2025
Also: Technical analysis for trading in shares of Nvidia, how MicroStrategy burns cash, and tips for people with student loans in 2025
Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman
Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025.
Biogen Faces Multiple Analyst Downgrades in December 2024
Biogen Faces Multiple Analyst Downgrades in December 2024